À¶Ý®ÊÓƵ

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
À¶Ý®ÊÓƵ

The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: IV-consensus guidelines for the management of post-transplant lymphoproliferative disorders in children and adolescents.

À¶Ý®ÊÓƵ

The IPTA Nashville consensus conference on post-transplant lymphoproliferative disorders after solid organ transplantation in children: IV-consensus guidelines for the management of post-transplant lymphoproliferative disorders in children and adolescents. Pediatric transplantation Allen, U. D., L'Huillier, A. G., Bollard, C. M., Gross, T. G., Hayashi, R. J., Höcker, B., Maecker-Kolhoff, B., Marks, S. D., Mazariegos, G. V., Smets, F., Trappe, R. U., Visner, G., Chinnock, R. E., Comoli, P., Danziger-Isakov, L., Dulek, D. E., Dipchand, A. I., Ferry, J. A., Martinez, O. M., Metes, D. M., Michaels, M. G., Preiksaitis, J., Squires, J. E., Swerdlow, S. H., Wilkinson, J. D., Dharnidharka, V. R., Green, M., Webber, S. A., Esquivel, C. O. 2024; 28 (5): e14781

Abstract

The International Pediatric Transplant Association convened an expert consensus conference to assess current evidence and develop recommendations for various aspects of care relating to post-transplant lymphoproliferative disorders (PTLD) after pediatric solid organ transplantation. This report addresses the outcomes of deliberations by the PTLD Management Working Group. A strong recommendation was made for reduction in immunosuppression as the first step in management. Similarly, strong recommendations were made for the use of the anti-CD20 monoclonal antibody (rituximab) as was the case for chemotherapy in selected scenarios. In some scenarios, there is uncoupling of the strength of the recommendations from the available evidence in situations where such evidence is lacking but collective clinical experiences drive decision-making. Of note, there are no large, randomized phase III trials of any treatment for PTLD in the pediatric age group. Current gaps and future À¶Ý®ÊÓƵ priorities are highlighted.

View details for

View details for